EXPERIENCE WITH SUBCUTANEOUS TRASTUZUMAB USED IN RUSSIAN FEDERATION

• Published in: Medicinskij sovet no. 14; pp. 40 - 45
• Main Authors: Lubennikova, E. V., Ganshina, I. P., Lud, A. N., Komov, D. V., Kolyadina, I. V., Vishnevskaya, Y. V., Vorotnikov, I. K., Stroyakovsky, D. L., Savelov, N. A., Semiglazov, V. F., Manikhas, А. G., Osheychik, А. V., Strelnikova, T. B., Zeynalova, K. R., Zhukova, L. G.
• Format: Journal Article
• Language: English
• Published: 14.11.2017
• ISSN: 2079-701X; 2658-5790
• DOI: 10.21518/2079-701X-2017-14-

The HannaH study showed that neoadjuvante-adjuvant subcutaneous and intravenous trastuzumab have similar efficacy and tolerability in patients with early HER2-positive breast cancer. The analysis of the results of the subcutaneous and intravenous trastuzumab usage in  Russian population showed  the favorable association between tpCR anf EFS. tpCR achiviement is associated with clinical benefit in HER2 positive breast cancer. For patients with difficult venous access who do not require intravenous chemotherapy currently, Subcutaneous trastuzumab allows  to receive effective treatment without the risk of complications, which involves catheterization of a Central vein.